溶血磷脂酸（lysophosphatidic acid，LPA）是一种对多种细胞具有不同生物学活性的磷脂介质，在组织中广泛存在。从细胞形态学改变到细胞功能的影响，LPA可产生如促进细胞增殖、迁移和耐药等生物学效应。如其他生物递质一样，LPA与细胞表面特定的G蛋白偶合受体（G protein-coupled receptor，GPCR）发生交联作用，这些受体主要有Edg-2/LPA1、Edg-4/LPA2和Edg-7/LPA3等，它们被命名为内皮分化基因或溶血磷脂受体亚家族（endothelial differentiation gene or lysophospholipid receptor subfamily，Edg/LPAR subfamily）。LPA在体内外参与细胞增殖以及血管生成等病理生理过程，LPA代谢和Edg/LPA受体功能的异常与肿瘤的发生、发展相关，可能是肿瘤临床诊治的潜在靶点。本文阐述了LPA通过Edg/LPA受体介导在肿瘤发生和发展中的作用及其机制，并就其在胰腺癌临床诊治中的意义进行了评价。

Lysophosphatidic acid (LPA) is a naturally occurring phospholipid with diverse effects on various cells, ranging from cellular morphology alterations to cellular function changes such as induction of cell proliferation, survival, drug resistance and motility. Like many other biomediators, LPA interacts with cells through specific cell surface receptors (G protein-coupled receptors). Edg-2/LPA1, Edg-4/LPA2 and Edg-7/LPA3, named as endothelial differentiation gene or lysophospholipidic receptor subfamily (Edg/LPA subfamily), are three most common LPA receptors. LPA plays a critical role as a general growth, survival and pro-angiogenic factor in the regulation of pathophysiological processes in vivo and in vitro. Recent reports in the literature suggest that abnormalities in LPA metabolism and Edg/LPA receptors function in cancer patients may contribute to the development and progression of the disease. Thus, LPA and its receptors might be potential targets for clinical cancer diagnosis and therapy. Herein we review the function and mechanism of LPA and its receptors in the development and progression of tumors with focus on human pancreatic cancer, and also clinical diagnosis and treatment has been evaluated.

江苏省卫生厅“科教兴卫工程”医学领军人才与创新团队专项基金资助（No. 2011-15）；南京医科大学医学重点科技发展项目资助（No. 08NMUZ042）；南京市医学重点科技发展项目资助（No. ZKX09007）